These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 19395457)

  • 21. Population pharmacokinetics of atacicept in systemic lupus erythematosus: An analysis of three clinical trials.
    Pitsiu M; Yalkinoglu Ö; Farrell C; Girard P; Vazquez-Mateo C; Papasouliotis O
    CPT Pharmacometrics Syst Pharmacol; 2023 Aug; 12(8):1157-1169. PubMed ID: 37332136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial.
    Merrill JT; Shanahan WR; Scheinberg M; Kalunian KC; Wofsy D; Martin RS
    Ann Rheum Dis; 2018 Jun; 77(6):883-889. PubMed ID: 29563108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.
    Kappos L; Hartung HP; Freedman MS; Boyko A; Radü EW; Mikol DD; Lamarine M; Hyvert Y; Freudensprung U; Plitz T; van Beek J;
    Lancet Neurol; 2014 Apr; 13(4):353-63. PubMed ID: 24613349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics, pharmacodynamics, and tolerability of single ascending doses of RCT-18 in Chinese patients with rheumatoid arthritis.
    Chen X; Hou Y; Jiang J; Zhao Q; Zhong W; Wang W; Yao X; Li L; Fang J; Zhang F; Hu P
    Clin Pharmacokinet; 2014 Nov; 53(11):1033-44. PubMed ID: 25179916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.
    Szepietowski JC; Nilganuwong S; Wozniacka A; Kuhn A; Nyberg F; van Vollenhoven RF; Bengtsson AA; Reich A; de Vries DE; van Hartingsveldt B; Robinson DW; Gordon R; Hsu B
    Arthritis Rheum; 2013 Oct; 65(10):2661-71. PubMed ID: 23896980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin.
    Dillon SR; Harder B; Lewis KB; Moore MD; Liu H; Bukowski TR; Hamacher NB; Lantry MM; Maurer M; Krejsa CM; Ellsworth JL; Pederson S; Elkon KB; Wener MH; Dall'Era M; Gross JA
    Arthritis Res Ther; 2010; 12(2):R48. PubMed ID: 20302641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus.
    Lu P; Fleischmann R; Curtis C; Ignatenko S; Clarke SH; Desai M; Wong SL; Grebe KM; Black K; Zeng J; Stolzenbach J; Medema JK
    Lupus; 2018 Feb; 27(2):290-302. PubMed ID: 28691866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. No interactions between heparin and atacicept, an antagonist of B cell survival cytokines.
    Kowalczyk-Quintas C; Willen D; Willen L; Golob M; Schuepbach-Mallepell S; Peter B; Eslami M; Vigolo M; Broly H; Samy E; Yalkinoglu Ö; Schneider P
    Br J Pharmacol; 2019 Oct; 176(20):4019-4033. PubMed ID: 31355456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atacicept as an investigated therapy for rheumatoid arthritis.
    Richez C; Truchetet ME; Schaeverbeke T; Bannwarth B
    Expert Opin Investig Drugs; 2014 Sep; 23(9):1285-94. PubMed ID: 25078871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles.
    Chamberlain C; Colman PJ; Ranger AM; Burkly LC; Johnston GI; Otoul C; Stach C; Zamacona M; Dörner T; Urowitz M; Hiepe F
    Ann Rheum Dis; 2017 Nov; 76(11):1837-1844. PubMed ID: 28780512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus.
    Bengtsson AA; Sturfelt G; Lood C; Rönnblom L; van Vollenhoven RF; Axelsson B; Sparre B; Tuvesson H; Ohman MW; Leanderson T
    Arthritis Rheum; 2012 May; 64(5):1579-88. PubMed ID: 22131101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial.
    van Vollenhoven RF; Wax S; Li Y; Tak PP
    Arthritis Rheumatol; 2015 Nov; 67(11):2828-36. PubMed ID: 26137975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus.
    Fan Y; Gao D; Zhang Z
    Drugs Today (Barc); 2022 Jan; 58(1):23-32. PubMed ID: 35107091
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.
    Furie R; Stohl W; Ginzler EM; Becker M; Mishra N; Chatham W; Merrill JT; Weinstein A; McCune WJ; Zhong J; Cai W; Freimuth W;
    Arthritis Res Ther; 2008; 10(5):R109. PubMed ID: 18786258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.
    Merrill JT; Wallace DJ; Petri M; Kirou KA; Yao Y; White WI; Robbie G; Levin R; Berney SM; Chindalore V; Olsen N; Richman L; Le C; Jallal B; White B;
    Ann Rheum Dis; 2011 Nov; 70(11):1905-13. PubMed ID: 21798883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atacicept: targeting B cells in multiple sclerosis.
    Hartung HP; Kieseier BC
    Ther Adv Neurol Disord; 2010 Jul; 3(4):205-16. PubMed ID: 21179612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders.
    Kaegi C; Steiner UC; Wuest B; Crowley C; Boyman O
    Front Immunol; 2020; 11():433. PubMed ID: 32265917
    [No Abstract]   [Full Text] [Related]  

  • 38. Kinetics of free and ligand-bound atacicept in human serum.
    Eslami M; Willen D; Papasouliotis O; Schuepbach-Mallpell S; Willen L; Donzé O; Yalkinoglu Ö; Schneider P
    Front Immunol; 2022; 13():1035556. PubMed ID: 36532058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosus.
    Witcher J; Fleischmann R; Chindalore VL; Hansen RJ; Hu L; Radtke D; Voelker J; Gomez E; McColm J
    Br J Clin Pharmacol; 2016 May; 81(5):908-17. PubMed ID: 26648084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics, pharmacodynamics, short term efficacy and safety of RCT-18, a novel BLyS/APRIL fusion protein, in patients with rheumatoid arthritis.
    Chen X; Zhao Q; Hou Y; Jiang J; Zhong W; Wang W; Yao X; Li L; Fang J; Zhang F; Hu P
    Br J Clin Pharmacol; 2016 Jul; 82(1):41-52. PubMed ID: 26917504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.